Faes Farma (XMAD:FAE) GF Value Rank: 10 (As of Jul. 27, 2026) — 67% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:FAE Faes Farma SA XMAD:FAE
93 GF Score
Price €4.57
GF Value €5.19
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Faes Farma GF Value Rank?

Faes Farma XMAD:FAE +0.55% 93 GF Value Rank is 10 as of Jul. 27, 2026, which is 67% above its 10-year median of 6.00. GuruFocus rates XMAD:FAE with a GF Score™ of 93/100 and a GF Value™ of €5.19 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Faes Farma has the GF Value Rank of 10.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


XMAD:FAE vs ZTS, UTHR, VTRS: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faes Farma GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Faes Farma's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Faes Farma's GF Value Rank falls into.


XMAD:FAE
93GF Score
Faes Farma SA XMAD:FAE
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 10 mean?
Faes Farma (XMAD:FAE) has a GF Value Rank of 10 as of Jul. 27, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Faes Farma and its competitors. This is 67% above median its historical median of 6.00. Over the past decade, Faes Farma's GF Value Rank has ranged from 1.00 to 10.00.
Is Faes Farma's GF Value Rank too high?
Faes Farma's current GF Value Rank of 10 is 67% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Faes Farma has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Faes Farma's GF Value Rank compare to ZTS and UTHR?
Faes Farma's GF Value Rank of 10 can be compared against companies in the Drug Manufacturers industry. Historically, Faes Farma's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Faes Farma and its competitors. Faes Farma's current GF Value Rank is 10, which is 67% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faes Farma stock overvalued right now?
Based on GuruFocus' analysis, Faes Farma (XMAD:FAE) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.19, compared to a current price of €4.57 — trading 12% below its estimated fair value. The current GF Value Rank is 10, which is 67% above median its 10-year median of 6.00. Faes Farma's overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Faes Farma (XMAD:FAE), the current GF Value Rank is 10 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Faes Farma (XMAD:FAE) Overvalued in 2026?

Based on GuruFocus' analysis, Faes Farma stock appears to be undervalued. The current stock price of €4.57 is trading 12% below its estimated GF Value™ of €5.19. GuruFocus considers Faes Farma to be Modestly Undervalued.

Key valuation signals for XMAD:FAE:

  • GF Value Rank: 10 (67% above median its 10-year median of 6.00)
  • GF Value™: €5.19 vs. price of €4.57 (12% below fair value)
  • GF Score™: 93/100 with 7 warning signs

No single metric tells the full story. See the XMAD:FAE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Faes Farma Business Description

Other Exchanges 0K9H:UKFFEA:Germany
Address Avenida Autonomia, 10, Leioa, Vizcaya, ESP, 48940
Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.
93GF Score

Get the complete analysis for XMAD:FAE

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.57
Price
€5.19
GF Value